Review: PD-L1 as an emerging target in the treatment and prevention of keratinocytic skin cancer.
PD-1
PD-L1
cSCC
immune checkpoint inhibitor
nonmelanoma skin cancer
Journal
Molecular carcinogenesis
ISSN: 1098-2744
Titre abrégé: Mol Carcinog
Pays: United States
ID NLM: 8811105
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
02
09
2022
received:
20
04
2022
accepted:
06
09
2022
pmc-release:
01
01
2024
pubmed:
20
9
2022
medline:
20
12
2022
entrez:
19
9
2022
Statut:
ppublish
Résumé
Recent advances in the understanding and targeting of immune checkpoints have led to great progress in immune therapies against many forms of cancer. While many types of immune checkpoints are currently targeted in the clinic, this review will focus on recent research implicating the programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) axis as an emerging focus for the treatment of keratinocytic tumors. PD-L1 is of particular interest in nonmelanoma skin cancer (NMSC), as it is not only upregulated in these tumors but is stimulated by environmental ultraviolet exposure. This response may also make PD-L1 an excellent target for photochemoprevention using topically applied small molecule inhibitors. Here, we summarize recent investigations on PD-L1 expression and clinically relevant immune checkpoint inhibitor treatment in cutaneous squamous cell carcinoma, basal cell carcinoma, and head and neck squamous cell carcinoma, as well as small molecule agents targeting PD-L1 that may be useful for clinical development aiming at treatment or prevention of NMSC.
Identifiants
pubmed: 36121318
doi: 10.1002/mc.23464
pmc: PMC9771956
mid: NIHMS1835932
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
Types de publication
Review
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
52-61Subventions
Organisme : NCI NIH HHS
ID : P30 CA023074
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA229112
Pays : United States
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Front Pharmacol. 2021 Jun 21;12:677120
pubmed: 34234673
J Natl Cancer Inst. 2008 Mar 19;100(6):407-20
pubmed: 18334711
Eur J Dermatol. 2008 Nov-Dec;18(6):677-82
pubmed: 18955210
Dermatol Surg. 2014 Dec;40(12):1395-401
pubmed: 25393350
Photochem Photobiol. 2021 Jul;97(4):778-784
pubmed: 33615483
Int J Dermatol. 1998 Sep;37(9):677-81
pubmed: 9762818
J Biol Chem. 2020 Apr 3;295(14):4372-4380
pubmed: 31882544
Dermatol Surg. 2015 Nov;41(11):1214-40
pubmed: 26445288
Indian J Dermatol. 2020 Nov-Dec;65(6):506-509
pubmed: 33487707
J Med Chem. 2019 May 9;62(9):4703-4715
pubmed: 30964291
Cancer. 2012 Oct 1;118(19):4768-76
pubmed: 22644960
J Med Chem. 2019 Feb 28;62(4):1715-1730
pubmed: 30247903
Adv Exp Med Biol. 2020;1268:123-139
pubmed: 32918216
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Carcinogenesis. 2014 Jun;35(6):1310-9
pubmed: 24469308
J Clin Oncol. 2022 Jul 20;40(21):2321-2332
pubmed: 35333599
J Med Chem. 2021 May 13;64(9):5519-5534
pubmed: 33938739
Biomed Res. 2019;40(6):243-250
pubmed: 31839668
Eur J Med Chem. 2020 Aug 1;199:112377
pubmed: 32388281
Acta Biomater. 2021 Nov;135:543-555
pubmed: 34400305
Cells. 2021 Jun 08;10(6):
pubmed: 34201301
JAMA Dermatol. 2015 Oct;151(10):1081-6
pubmed: 25928283
Clin Investig. 1992 Mar-Apr;70(3-4):320-7
pubmed: 1521046
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
Ther Adv Med Oncol. 2022 Jan 19;14:17588359211066147
pubmed: 35082923
Structure. 2017 Aug 1;25(8):1163-1174
pubmed: 28768162
Phys Med Biol. 2004 Jan 7;49(1):R1-11
pubmed: 14971768
N Engl J Med. 2007 May 10;356(19):1944-56
pubmed: 17494927
Pharmaceutics. 2021 Apr 21;13(5):
pubmed: 33919384
Ann Oncol. 2020 Jul;31(7):942-950
pubmed: 32294530
Oncologist. 2021 May;26(5):433-438
pubmed: 33687763
Cancer Res. 2011 Jul 15;71(14):4737-41
pubmed: 21730022
J Med Chem. 2020 Aug 13;63(15):8338-8358
pubmed: 32667799
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Curr Oncol Rep. 2021 Aug 27;23(11):125
pubmed: 34448958
JAMA Dermatol. 2017 Apr 1;153(4):285-290
pubmed: 28259105
J Clin Med. 2015 Jun 03;4(6):1229-39
pubmed: 26239556
Br J Dermatol. 2017 Aug;177(2):350-358
pubmed: 27500794
J Clin Oncol. 2012 Jun 10;30(17):2102-11
pubmed: 22565003
Commun Biol. 2021 Jun 8;4(1):699
pubmed: 34103659
J Thorac Oncol. 2019 Oct;14(10):1794-1806
pubmed: 31228626
Mol Cell. 2019 Nov 7;76(3):359-370
pubmed: 31668929
N Engl J Med. 2022 Feb 3;386(5):449-462
pubmed: 35108470
J Med Chem. 2021 Nov 11;64(21):16020-16045
pubmed: 34670084
Nat Rev Immunol. 2008 Jun;8(6):467-77
pubmed: 18500231
J Extracell Vesicles. 2019 Dec 27;9(1):1709262
pubmed: 33133428
Front Immunol. 2019 Oct 04;10:2298
pubmed: 31636634
Nat Rev Immunol. 2015 Jan;15(1):45-56
pubmed: 25534622
Front Pharmacol. 2019 Jan 09;9:1503
pubmed: 30687086
Case Rep Dermatol. 2020 Feb 12;12(1):37-41
pubmed: 32595466
JAMA Dermatol. 2013 May;149(5):541-7
pubmed: 23677079
J Autoimmun. 2014 Sep;53:1-9
pubmed: 25047812
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Oncogene. 2018 Aug;37(34):4639-4661
pubmed: 29765155
Radiat Oncol. 2021 Apr 9;16(1):69
pubmed: 33836800
Cancer Immunol Immunother. 2017 Sep;66(9):1199-1204
pubmed: 28501937
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Anticancer Res. 2021 Jul;41(7):3439-3448
pubmed: 34230139
Bioorg Chem. 2021 Jun;111:104833
pubmed: 33839580
J Am Acad Dermatol. 2021 Sep;85(3):741-743
pubmed: 31499148
Front Oncol. 2018 Sep 19;8:386
pubmed: 30283733
J Immunol. 2010 May 1;184(9):4918-25
pubmed: 20363965
Mol Cancer. 2019 Nov 6;18(1):155
pubmed: 31690319
Bosn J Basic Med Sci. 2022 Oct 23;22(6):894-900
pubmed: 35801411
Lancet Oncol. 2015 Jun;16(6):716-28
pubmed: 25981810
Cancer Res. 2011 Feb 15;71(4):1235-43
pubmed: 21159661
Am J Cancer Res. 2020 Mar 01;10(3):727-742
pubmed: 32266087
Expert Rev Clin Pharmacol. 2019 Oct;12(10):947-951
pubmed: 31524530
Br J Dermatol. 2017 May;176(5):1354-1356
pubmed: 27516151
J Cutan Pathol. 2016 Aug;43(8):663-70
pubmed: 27153517
Eur J Med Chem. 2021 May 5;217:113377
pubmed: 33770574
Pharmacol Res. 2018 Sep;135:166-180
pubmed: 30103001
Lancet Oncol. 2020 Feb;21(2):294-305
pubmed: 31952975
N Engl J Med. 2011 Jun 30;364(26):2517-26
pubmed: 21639810
JAAD Case Rep. 2021 Oct 20;18:23-25
pubmed: 34778502
J Am Acad Dermatol. 1991 May;24(5 Pt 1):715-9
pubmed: 1869642
Photochem Photobiol Sci. 2008 Jun;7(6):730-3
pubmed: 18528559
BMC Cancer. 2017 May 16;17(1):332
pubmed: 28511673
Am Health Drug Benefits. 2015 Mar;8(Spec Feature):96-100
pubmed: 26629272
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Small. 2019 Dec;15(49):e1903881
pubmed: 31702880
Front Oncol. 2022 Jan 05;11:727027
pubmed: 35070956
Expert Rev Anticancer Ther. 2022 Mar;22(3):243-248
pubmed: 35175882
AAPS J. 2021 Mar 7;23(2):39
pubmed: 33677681
Pharmacol Ther. 2019 Feb;194:84-106
pubmed: 30268773
JAAD Case Rep. 2019 Jun 08;5(6):514-517
pubmed: 31205993
Rev Environ Health. 2012;27(2-3):103-16
pubmed: 23023879
Dermatol Surg. 2007 Aug;33(8):885-99
pubmed: 17661931
J Periodontol. 2022 Jan;93(1):146-155
pubmed: 34021604
Oncotarget. 2017 Aug 7;8(42):72167-72181
pubmed: 29069777
Am J Prev Med. 2015 Feb;48(2):183-187
pubmed: 25442229